Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
By R. Motzer, B. Rini, D. McDermott, B. Redman, T. Kuzel, M. Harrison, U. Vaishampayan, H. Drabkin, S. George, T. Logan and 5 more. Journal of Clinical Oncology, 2014
1,015 citations recorded by the source corpus.
Purpose Nivolumab is a fully human immunoglobulin G4 programmed death–1 immune checkpoint inhibitor antibody that restores T-cell immune activity. This phase II trial assessed the antitumor activity, dose-response relationship, and safety of nivolumab in patients with metastatic renal cell carcinoma (mRCC). Patients and Methods Patients with clear-cell mRCC previously treated with agents targeting the vascular endothelial growth factor pathway were randomly assigned (blinded ratio of 1:1:1) to nivolumab 0.3, 2, or 10 mg/kg intravenously once every 3 weeks. The primary objective was to evaluate the dose-response relationship as measured by progression-free survival (PFS); secondary end points included objective response rate (ORR), overall survival (OS), and safety. Results A total of 168 patients were randomly assigned to the nivolumab 0.3- (n = 60), 2- (n = 54), and 10-mg/kg (n = 54) cohorts. One hundred eighteen patients (70%) had received more than one prior systemic regimen. Median PFS was 2.7, 4.0, and 4.2 months, respectively (P = .9). Respective ORRs were 20%, 22%, and 20%. Median OS was 18.2 months (80% CI, 16.2 to 24.0 months), 25.5 months (80% CI, 19.8 to 28.8 months), and 24.7 months (80% CI, 15.3 to 26.0 months), respectively. The most common treatment-related adverse event (AE) was fatigue (24%, 22%, and 35%, respectively). Nineteen patients (11%) experienced grade 3 to 4 treatment-related AEs. Conclusion Nivolumab demonstrated antitumor activity with a manageable safety profile across the three doses studied in mRCC. No dose-response relationship was detected as measured by PFS. These efficacy and safety results in mRCC support study in the phase III setting.
Subfields: Oncology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/d2ada167eedea8839ae1bccf4c9d93e96801041c
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
Citations in the corpus
- Management of toxicities of immune checkpoint inhibitors. (2016, background): “[13] Rates of AEs from nivolumab at 3mg/kg and 10mg/kg appear very similar.[22, 78] An analysis in melanoma patients of long-term nivolumab safety with evaluations up to 2 years, did not reveal cumulative toxicities with ongoing treatment.”
- Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. (2016, background): “These agents, together with pidilizumab, and two anti-PD-L1 mAbs durvalumab (MEDI4736) and atezolizumab (MPDL3280A) that target the PD-1 ligand PD-L1, have demonstrated antitumor activity in a number of tumor types, including: renal cell carcinoma (RCC) [5], urothelial carcinoma [6], Hodgkin’s lymph”
- Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab. (2016, background): “of injections before onset of vitiligo, median (range) 7 (4-31)”
- CTLA-4 and PD-1 Pathways (2016, background): “Unconventional response patterns have also been observed in patients with lung cancer or RCC receiving PD-1 pathway inhibitors.(56,64,65,70) These atypical responses have led to the development of modified response criteria called immunerelated response criteria (Supplemental Table 1, Supplemental D”
- Nivolumab versus Everolimus in Advanced Renal Cell Carcinoma (2015, neutral): “Pneumonitis 16 (4) 6 (1) 58 (15) 11 (3)”
- Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis (2017, background): “001) (Figure 2).(14-50) The predicted incidence of hypothyroidism ranged from 3.”